RTI Biologics, Inc. (RTIX) Tops Q2 EPS by 1c; Guides Q3; Adjusts FY12 Numbers
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Financial Fact:
Total other expense - net: -374K
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total other expense - net: -374K
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q2 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $45.2 million versus the consensus estimate of $44.24 million.
RTI Biologics, Inc. sees FY2012 EPS of $0.14-$0.15, versus prior guidance of $0.16-$0.17 and the consensus of $0.17. RTI Biologics, Inc. sees FY2012 revenue of $177-$178 million, versus prior guidance of $176-$178 million and the consensus of $177.24 million.
Sees Q3 2012 revenue of $44-$45 million, versus the consensus of $43.49 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
RTI Biologics, Inc. sees FY2012 EPS of $0.14-$0.15, versus prior guidance of $0.16-$0.17 and the consensus of $0.17. RTI Biologics, Inc. sees FY2012 revenue of $177-$178 million, versus prior guidance of $176-$178 million and the consensus of $177.24 million.
Sees Q3 2012 revenue of $44-$45 million, versus the consensus of $43.49 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
